| Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig C Lei, K Qian, T Li, S Zhang, W Fu, M Ding, S Hu Nature communications 11 (1), 1-5, 2020 | 417 | 2020 |
| CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity W Fu, C Lei, S Liu, Y Cui, C Wang, K Qian, T Li, Y Shen, X Fan, F Lin, ... Nature communications 10 (1), 1-12, 2019 | 398 | 2019 |
| Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor α-associated diseases from a molecular view S Hu, S Liang, H Guo, D Zhang, H Li, X Wang, W Yang, W Qian, S Hou, ... Journal of Biological Chemistry 288 (38), 27059-27067, 2013 | 192 | 2013 |
| Structural basis for treating tumor necrosis factor α (TNFα)-associated diseases with the therapeutic antibody infliximab S Liang, J Dai, S Hou, L Su, D Zhang, H Guo, S Hu, H Wang, Z Rao, ... Journal of Biological Chemistry 288 (19), 13799-13807, 2013 | 141 | 2013 |
| Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk S Hu, W Fu, W Xu, Y Yang, M Cruz, SD Berezov, D Jorissen, H Takeda, ... Cancer research 75 (1), 159-170, 2015 | 95 | 2015 |
| Bispecific Antibody to ErbB2 Overcomes Trastuzumab Resistance through Comprehensive Blockade of ErbB2 HeterodimerizationAn Anti-ErbB2 BsAb Circumvents Trastuzumab Resistance B Li, Y Meng, L Zheng, X Zhang, Q Tong, W Tan, S Hu, H Li, Y Chen, ... Cancer Research 73 (21), 6471-6483, 2013 | 77 | 2013 |
| Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency S Hu, W Fu, T Li, Q Yuan, F Wang, G Lv, Y Lv, X Fan, Y Shen, F Lin, ... Science Translational Medicine 9 (380), eaag0339, 2017 | 70 | 2017 |
| SOX10, a novel HMG-box-containing tumor suppressor, inhibits growth and metastasis of digestive cancers by suppressing the Wnt/β-catenin pathway X Tong, L Li, X Li, L Heng, L Zhong, X Su, R Rong, S Hu, W Liu, B Jia, ... Oncotarget 5 (21), 10571, 2014 | 70 | 2014 |
| Molecular architecture of the ErbB2 extracellular domain homodimer S Hu, Y Sun, Y Meng, X Wang, W Yang, W Fu, H Guo, W Qian, S Hou, B Li, ... Oncotarget 6 (3), 1695, 2015 | 57 | 2015 |
| The roles of small extracellular vesicles in cancer and immune regulation and translational potential in cancer therapy K Qian, W Fu, T Li, J Zhao, C Lei, S Hu Journal of Experimental & Clinical Cancer Research 41 (1), 1-29, 2022 | 44 | 2022 |
| EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumor-Initiating Cell FrequencyTargeting CSC with Anti-EGFR/Notch Antibody W Fu, C Lei, Y Yu, S Liu, T Li, F Lin, X Fan, Y Shen, M Ding, Y Tang, X Ye, ... Clinical Cancer Research 25 (9), 2835-2847, 2019 | 36 | 2019 |
| CAR macrophages for SARS-CoV-2 immunotherapy W Fu, C Lei, Z Ma, K Qian, T Li, J Zhao, S Hu Frontiers in Immunology, 2907, 2021 | 34 | 2021 |
| The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer S Han, Y Meng, Q Tong, G Li, X Zhang, Y Chen, S Hu, L Zheng, W Tan, ... MAbs 6 (2), 403-408, 2014 | 34 | 2014 |
| Treatment of murine lupus with TIGIT-Ig S Liu, L Sun, C Wang, Y Cui, Y Ling, T Li, F Lin, W Fu, M Ding, S Zhang, ... Clinical Immunology 203, 72-80, 2019 | 30 | 2019 |
| Effective suppression of breast tumor growth by an anti-EGFR/ErbB2 bispecific antibody S Wang, C Chen, Y Meng, S Hu, L Zheng, J Song, D Zhang, B Li, Y Guo Cancer letters 325 (2), 214-219, 2012 | 30 | 2012 |
| Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer S Hu, H Dai, T Li, Y Tang, W Fu, Q Yuan, F Wang, G Lv, Y Lv, X Fan, ... Cancer Letters 382 (1), 32-43, 2016 | 27 | 2016 |
| Targeting EGFR/HER2 heterodimerization with a novel anti-HER2 domain II/III antibody X Yu, L Wang, Y Shen, C Wang, Y Zhang, Y Meng, Y Yang, B Liang, ... Molecular Immunology 87, 300-307, 2017 | 20 | 2017 |
| Treatment of murine lupus with PD-LIg H Zhou, L Xiong, Y Wang, L Ding, S Hu, M Zhao, L Zhou Clinical Immunology 162, 1-8, 2016 | 19 | 2016 |
| TIGIT-Fc Promotes Antitumor ImmunityTIGIT-Fc Promotes Antitumor Immunity X Shen, W Fu, Y Wei, J Zhu, Y Yu, C Lei, J Zhao, S Hu Cancer Immunology Research 9 (9), 1088-1097, 2021 | 11 | 2021 |
| TIGIT-Fc as a potential therapeutic agent for fetomaternal tolerance W Fu, R Cai, Z Ma, T Li, C Lei, J Zhao, S Hu Frontiers in immunology 12, 649135, 2021 | 11 | 2021 |
